Dishman Carbogen Amcis Limited announced that the company's Bavla facility was successfully inspected by the US FDA in October 2018, which was intimated to the stock exchange on October 27, 2018. The company has received the Establishment Inspection Report (EIR) from the US FDA for this facility On January 28, 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
168 INR | +0.18% |
|
-0.44% | -1.67% |
28/06 | Dishman Carbogen Amcis Receives FDA Clearance for Swiss Manufacturing Facilities | MT |
31/05 | Transcript : Dishman Carbogen Amcis Limited, Q4 2024 Earnings Call, May 31, 2024 |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+61.53% | 85TCr | |
+33.48% | 63TCr | |
-3.66% | 36TCr | |
+15.06% | 32TCr | |
+9.18% | 30TCr | |
+11.90% | 23TCr | |
+16.24% | 23TCr | |
+15.67% | 18TCr | |
+2.47% | 17TCr |
- Stock Market
- Equities
- DCAL Stock
- DCAL Stock
- News Dishman Carbogen Amcis Limited
- Dishman Carbogen Amcis Limited Receives Approval from US FDA for Bavla Facility